INVO Fertility Q2 Revenue Up 17%, Clinic Platform Turns Profitable
IVF has more than doubled off its 52-week low of $0.9.
Summary
INVO Fertility's Q2 revenue rose 17% to $2.18M and the company swung to a $0.9M net profit, driven by a $2.5M remeasurement gain on the Birmingham acquisition. Clinic-level Adjusted EBITDA reached $333K.
Key Events · Earnings and Guidance · IVF
-
Revenue Up 17%
Q2 2026 revenue was $2,175,485, up from $1,863,654 in Q2 2025, driven by the Family Beginnings acquisition and organic growth.
-
Net Income Swings Positive
Net income was $0.9 million versus a net loss of $3.6 million a year ago, including a $2.5 million gain on remeasurement of the Birmingham acquisition.
-
Clinic Platform Profitable
Clinic-Level Adjusted EBITDA was $333,000 in Q2 2026, up from $164,000 in Q1 2026 and $951,000 for all of 2025.
-
Cash Position
Cash was $3.7 million at June 30, 2026, up from $2.1 million at December 31, 2025.
Analysis · IVF · Industrial Applications And Services
INVO Fertility reported Q2 2026 revenue of $2.18 million, up 17% year-over-year, and swung to net income of $0.9 million from a $3.6 million loss a year ago. The clinic platform generated $333,000 in Adjusted EBITDA before corporate expenses, up from $164,000 in Q1. Cash stood at $3.7 million. The company remains a going concern with a highly dilutive equity line in place, but these results show the core clinic operations are gaining traction.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1516 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVF was trading at $2.46 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.90 to $84.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.